Johnson and Johnson COVID Vaccine on ‘Pause’ After FDA, CDC Report Rare Blood Clot Issues
The Biden administration called for a ‘pause’ in administering the Johnson and Johnson COVID-19 China coronavirus vaccine Tuesday morning. The FDA and CDC, citing six reports of blood clots in women aged 18-48–including one fatality–out of about seven million administered vaccines, called on states to ‘pause’ the J&J vaccine while the problem is studied. The similar AstraZeneca vaccine deployed in Europe has faced similar rare clotting issues. The New York Times was first to report on the ‘pause’.
Breaking News: The U.S. will seek to pause Johnson & Johnson’s coronavirus vaccine after six women developed rare blood clots, officials briefed on the decision said.https://t.co/9cnE2E0Ehn
— The New York Times (@nytimes) April 13,
